BU BSL-4 lab faces more scrutiny

Infections of three lab workers with tularemia at BSL-2 lab puts plan in spotlight again

Written byClare Kittredge
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The city of Boston plans to toughen up laboratory safety protocols after revelations that three Boston University (BU) researchers were accidentally infected with a lethal strain of tularemia they thought was harmless.

The illnesses last year were made public January 18 by university and public health authorities, a day before a "dirty bomb" scare rocked the city. That was some 2 months after BU reported the cases to public health officials.

Word of the contaminations—two last May and one in September—and the delay in making them public intensified controversy over plans to build a $178 million Biosafety Level 4 (BSL-4) research lab at BU in a crowded urban neighborhood.

Some critics accused authorities of delaying the revelations until after public hearings on the BSL-4 lab, which earlier this month won approval from the city's zoning commission.

While federal investigators probed how a deadly strain of tularemia wound up in a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform